Dr. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks. Ginkgo is a synthetic biology company that programs cells for customers in the chemical, pharmaceutical, food and energy industries. The company recently raised over $430M in venture capital to expand their automated genetic engineering foundries. They have a $100M joint venture with Bayer to develop microbes for self-fertilizing crops, a $160M partnership with Roche to develop antibiotics and with Motif for making animal-free protein ingredients. They have been listed for the past three years on CNBC's Disruptor 50 List of fast-growing companies. Prior to Ginkgo, Jason received B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering all from MIT.